Pharmacogenetic analysis of TS and UGT1A polymorphisms predictive for response and toxicity in Spanish patients with advanced colorectal cancer treated with first-line irinotecan and 5-fluorouracil

被引：0
|
作者：
Martinez-Balibrea, E. [1 ,2 ,3 ,4 ,5 ,6 ]
Abad, A. [1 ,2 ,3 ,4 ,5 ,6 ]
Valladares, M. [1 ,2 ,3 ,4 ,5 ,6 ]
Martinez-Villacampa, M. [1 ,2 ,3 ,4 ,5 ,6 ]
Aranda, E. [1 ,2 ,3 ,4 ,5 ,6 ]
Marcuello, E. [1 ,2 ,3 ,4 ,5 ,6 ]
Benavides, M. [1 ,2 ,3 ,4 ,5 ,6 ]
Martinez-Cardus, A. [1 ,2 ,3 ,4 ,5 ,6 ]
Gines, A. [1 ,2 ,3 ,4 ,5 ,6 ]
Manzano, J. L. [1 ,2 ,3 ,4 ,5 ,6 ]
机构：
[1] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain
[2] Hosp Juan Canalejo, La Coruna, Spain
[3] Hosp Duran & Reynals, ICO, Lhospitalet De Llobregat, Spain
[4] Hosp Reina Sofia, Cordoba, Spain
[5] Hosp Sant Pau, Barcelona, Spain
[6] Hosp Carlos Haya, Malaga, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4066
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Mismatch repair status is a predictive factor of tumour response to 5-fluorouracil and irinotecan chemotherapy in patients with advanced colorectal cancer
    Bendardaf, R.
    Lamlum, H.
    Ristamaki, R.
    Korkeila, E.
    Syrjanen, K.
    Pyrhonen, S.
    TUMOR BIOLOGY, 2007, 28 (04) : 212 - 220
  • [32] Polymorphisms in UGT1A1 and UGT1A7 may predict irinotecan toxicity in patients with advanced colorectal cancer
    Lastraioli, S.
    Ponzanelli, A.
    Leonardi, F.
    Marroni, P.
    Serra, M.
    Sonaglio, C.
    Loiacono, F.
    Zuccaro, D.
    Naldi, N.
    Franzini, E.
    Boni, L.
    Paganuzzi, M.
    Ardizzoni, A.
    Chiara, S.
    Notaro, R.
    ANNALS OF ONCOLOGY, 2006, 17 : XI47 - XI47
  • [33] Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting
    Lu, Chien-Yu
    Huang, Ching-Wen
    Hu, Huang-Ming
    Tsai, Hsiang-Lin
    Huang, Chun-Ming
    Yu, Fang-Jung
    Huang, Ming-Yii
    Chang, Se-Fen
    Huang, Meng-Lin
    Wang, Jaw-Yuan
    TRANSLATIONAL RESEARCH, 2014, 164 (02) : 169 - 176
  • [34] Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab
    Vincenzo Formica
    Raffaele Palmirotta
    Girolamo Del Monte
    Annalisa Savonarola
    Giorgia Ludovici
    Maria Laura De Marchis
    Italia Grenga
    Michele Schirru
    Fiorella Guadagni
    Mario Roselli
    International Journal of Colorectal Disease, 2011, 26 : 143 - 151
  • [35] Efficacy of sequential use of docetaxel / 5-fluorouracil / cisplatin as first-line, and irinotecan/levofolinate/5-fluorouracil as second-line chemotherapy for advanced gastric cancer
    Sugiyama, K.
    Ishikawa, A.
    Sato, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab
    Formica, Vincenzo
    Palmirotta, Raffaele
    Del Monte, Girolamo
    Savonarola, Annalisa
    Ludovici, Giorgia
    De Marchis, Maria Laura
    Grenga, Italia
    Schirru, Michele
    Guadagni, Fiorella
    Roselli, Mario
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2011, 26 (02) : 143 - 151
  • [37] Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil
    Pfeiffer, Per
    Nielsen, Dorte
    Yilmaz, Mette
    Iversen, Anja
    Vejlo, Christian
    Jensen, Benny Vittrup
    ACTA ONCOLOGICA, 2007, 46 (05) : 697 - 701
  • [38] Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study
    Kalofonos, HP
    Aravantinos, G
    Kosmidis, P
    Papakostas, P
    Economopoulos, T
    Dimopoulos, M
    Skarlos, D
    Bamias, A
    Pectasides, D
    Chalkidou, S
    Karina, M
    Koutras, A
    Samantas, E
    Bacoyiannis, C
    Samelis, GF
    Basdanis, G
    Kalfarentzos, F
    Fountzilas, G
    ANNALS OF ONCOLOGY, 2005, 16 (06) : 869 - 877
  • [39] Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer
    Kuehr, T
    Ruff, P
    Rapoport, BL
    Falk, S
    Daniel, F
    Jacobs, C
    Davidson, N
    Thaler, J
    Boussard, B
    Carmichael, J
    BMC CANCER, 2004, 4 (1)
  • [40] Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer
    Thomas Kuehr
    Paul Ruff
    Bernardo L Rapoport
    Stephen Falk
    Francis Daniel
    Conrad Jacobs
    Neville Davidson
    Josef Thaler
    Blandine Boussard
    James Carmichael
    BMC Cancer, 4
12345